Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315).

Griesinger F, Eberhardt WEE, Nusch A, Reiser M, Zahn MO, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Waller CF, Reck M, Christopoulos P, Sebastian M, Thomas M, 2019.

Ann Oncol. 2019;30 (suppl. 5)(1552P (ID: 3764)):mdz260.074

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2019
Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Lüftner D, Welslau M, Liersch R, Deryal M, Brucker C, Rauh J, Welt A, Zaiss M, Sahlmann J, Houet L, Vannier C, Potthoff K, Marschner N, 2019.

Ann Oncol, Volume 30, v135

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
INGE-B
2019
Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany.

Goebell PJ, Müller L, Grüllich C, Reichert D, Bögemann M, Dörfel S, von der Heyde E, Binninger A, Jänicke M, Marschner N, Staehler M, Grünwald V, 2019.

Ann Oncol, Volume 30, v135

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
CARAT
2019
Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma – Data from the prospective German Tumour Registry Lymphatic Neoplasms.

Knauf, W., Abenhardt, W., Mohm, J., Rauh, J., Harde, J., Kaiser-Osterhues, A., Jänicke, M., Marschner, N., TLN-Group; 2019.

Eur J Haematol 00, 1–12. doi:10.1111/ejh.13295

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: European Journal of Hematology
TLN
2019
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

C C Schimanski, S Kasper, S Hegewisch-Becker, J Schroeder, F Overkamp, F Kullmann, W O Bechstein, M Vöhringer, R Oellinger, F Lordick, V Heinemann, M Geissler, A Schulz-Abelius, B Linz, H Bernhard, M R Schoen, R Greil, V Smith-Machnow, I Schmidtmann, M H Moehler, 2019.

Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 3537-3537. DOI: 10.1200/JCO.2019.37.15_suppl.3537

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
LICC
2019
Twice weekly carfilzomib is an accepted treatment by patients with Multiple Myeloma who have received at least one prior therapy: Interim results if the CARO study.

W. Knauf; A. Ammon; J. Uhlig; M. Merling; H.-J. Hurtz; T. Riedt; H. Schulz; C. Vannier; N. Marschner; K. Potthoff; 2019.

HemaSphere. 3():646–647, JUN 2019 DOI: 10.1097/01.HS9.0000563904.96659.51 Issn Print: 2572-9241

Abstract
Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
CARO
2019
Lenalidomide in combination with dexamethasone as first-line therapy in transplant-ineligible patients with Multiple Myeloma: Interim Results of the observational study FIRST-NIS.

H. Nückel; H.-J. Hurtz; H. Schulz; M. Schulze; M. Koenigsmann; T. Dechow; M. Merling; L. Houet; C. Vannier; K. Potthoff; 2019.

HemaSphere. 3():263–264, JUN 2019 DOI: 10.1097/01.HS9.0000560764.61601.55 Issn Print: 2572-9241

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
FIRST-NIS
2019
Pertuzumab beim HER2-positiven metastasierten Mammakarzinom in der Routinebehandlung – Daten aus dem Tumorregister Mammakarzinom.

Overkamp, F; Frühauf, S; Fietz, T; Behringer, J; Kruggel, L; Wetzel, N; Marschner, N, 2019.

Senologie 2019; 16(02): 31 – 31 DOI: 10.1055/s-0039-1688031

Abstract
Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
TMK
2019
Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.

M Boegemann, J Bedke, M Schostak, C Hering-Schubert, M Welslau, J Schleicher, T Wolf, A Petzoldt, C Doehn, C Grüllich, V Grünwald, T Steiner, A Rogler, S Hanson, D Klein, T Medinger, PJ Goebell, 2019.

J Clin Oncol 2019 37:15_suppl, 4574-4574

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
PAZOREAL
2019
Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

A Welt, M K Welslau, D Lüftner, M Deryal, R Liersch, J Sahlmann, L Houet, C Vannier, N Marschner, K Potthoff, 2019.

Ann Oncol Volume 30, Issue Supplement_3, May 2019, mdz100.007, https://doi.org/10.1093/annonc/mdz100.007

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
INGE-B
2019